Institute for Cancer Research

 

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Harald Stenmark<br>Acting Inst. Head
Harald Stenmark
Acting Inst. Head

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
2017 so far  
 2016 235  
2015 221 21
2014 174 25
2013 205 27

Annual report 2015 (pdf format)

 

Latest news

CanCell – a new Centre of Excellence – will reprogram cancer cells

 

“Centre for Cancer Cell Reprogramming”, affiliated with the Institute of Clinical Medicine at University of Oslo, has been funded by the Research Council of Norway as a new Centre of Excellence.

 
 

New group leader at the Institute for Cancer Research:

Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology

 
Jørgen Wesche
Jørgen Wesche

Jørgen Wesche earned his PhD in Sjur Olsnes's group in 2001, studying intracellular transport and membrane translocation. During his postdoctoral training, spending some time at Institute Curie in Paris, he has changed his focus towards problems with more translational relevance, specializing in live cell imaging, fibroblast growth factor receptor (FGFR) signaling and importance of FGFR in cell migration/invasion. Aberrations in FGFR signaling are found in several types of sarcoma and that´s the main reason way Jørgen started to get interested in sarcoma biology and treatment. He has several exciting ideas on how to further develop his research into more translational/clinical relevance.

 
 

King Olav V´s Cancer Research Prize to Per O. Seglen

Prestigious research prize from the Norwegian Cancer Society to pioneer in autophagy research

 
Per O. Seglen (left) and 2016 Nobel laureate Yoshinori Ohsumi
Per O. Seglen (left) and 2016 Nobel laureate Yoshinori Ohsumi

Professor Per Ottar Seglen, formerly head of the Proteomics & Mammalian Cell Biology Section at the Institute for Cancer Research, OUH, currently a guest researcher at NCMM, has been awarded the prestigious King Olav V’s prize for Cancer Research 2017.

The award, formally announced by the Norwegian Cancer Society today, is recognized as one of the Norwegian cancer research community’s most respected prizes. Professor Seglen has been awarded the prize in recognition of his ground-breaking research into autophagic-lysosomal protein degradation and its relationship to cancer.

The prize will be officially presented by King Harald V, on behalf of the Cancer Society, at a special ceremony on 6 June 2017. The prize is NOK 1 million.

 
 

NORMENT study published in Nature Neuroscience:

Early signs of mental illness in the developing brain

 
Tobias Kaufmann (left) and Lars T. Westlye
Tobias Kaufmann (left) and Lars T. Westlye

Like a fingerprint, the connections of the human brain render us distinct from one another. In a study published in the February 20th issue of Nature Neuroscience (journal impact factor 16.7), entitled "Delayed stabilization and individualization in connectome development are related to psychiatric disorders", researchers at NORMENT reveal that such a unique, fingerprint-like pattern evolves during development and is sensitive to mental health. First and last authors are Tobias Kaufmann and Lars T. Westlye (photo).
The study has already gained attention, and the results have been discussed in articles published in Science Daily and Medical News Today.

 
 

OUH research seminar, Monday, March 6th 14:30

Health after transplantation

 

Welcome to the next Oslo University Hospital research seminar entitled "Health after transplantation".

Time: Monday, March 6th, 2017, at 14:30 – 16:00.
Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo.

 
 

Critical article on doping and drug testing published in EMBO reports

 
First author Erik Boye (left) and Tore Skotland
First author Erik Boye (left) and Tore Skotland

Sports play an important role in our society. Four Norwegian researchers, two from OUS, have published an article in EMBO reports where they discuss problems occurring in the testing of athletes for doping.
The authors (E. Boye and T. Skotland from OUS (photo), J. Nissen-Meyer from UiO and B. Østerud, UiTø) describe how the World Antidoping Agency (WADA) pretends never to make mistakes and is resistant to any form of discussion with other scientists. This attitude creates false positives and athletes are being sanctioned while innocent, with dramatic consequences for the individual. It is argued that both the technological, ethical and legal procedures should be revised and an independent body should monitor the function of WADA.